Conjunctival melanomas harbor BRAF and NRAS mutations-letter

Clinical Cancer Research

Volumn 19, Issue 22, 2013, Pages 6329-6330

  Weber, Jaimie L ^a   Smalley, Keiran S M ^b   Sondak, Vernon K ^b   Gibney, Geoffrey T ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VEMURAFENIB;

ADULT; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BRAF GENE; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CHROMOSOME LOSS; CLINICAL EVALUATION; CONJUNCTIVA MELANOMA; CONJUNCTIVA TUMOR; CORNEA; CUTANEOUS MELANOMA; GENE DOSAGE; GENE LOCUS; GENE MUTATION; GENETIC SIMILARITY; HUMAN; LETTER; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MALE; MELANOMA; MELANOMA METASTASIS; METASTASIS POTENTIAL; NRAS GENE; ONCOGENE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PTEN GENE; PYROSEQUENCING; RETROPERITONEUM; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR GROWTH;

CONJUNCTIVAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84888113585     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2007     Document Type: Letter

References (5)

1. Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, et al. Conjunctival melanomas harbor BRAF and NRASmutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 2013;19:3143-52.
2. Lake SL, Jmor F, Dopierala J, Taktak AF, Coupland SE, Damato BE. Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes. Invest Ophthalmol Vis Sci 2011;52:5598-604.
3. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 2013;14:e60-9.
4. Westekemper H, Karimi S, Susskind D, Anastassiou G, Freistuhler M, Steuhl KP, et al. Expression of HSP 90, PTEN and Bcl-2 in conjunctival melanoma. Br J Ophthalmol 2011;95:853-8.
5. Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 2013;19:4868-78.